Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.

Weiner, L M

Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. [electronic resource] - Cancer research Jul 1989 - 4062-7 p. digital

Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.

0008-5472


Antibodies, Monoclonal--adverse effects
Breast Neoplasms--drug therapy
Drug Evaluation
Female
Half-Life
Humans
Immunotoxins--adverse effects
Neoplasm Metastasis
Recombinant Proteins--adverse effects
Ricin--adverse effects